Drudge: ‘New Low’ for Ambien Maker to Mock Roseanne ‘While They Drug a Generation

http://www.breitbart.com/big-journalism/2018/05/30/matt-drudge-ambien-maker-mocking-roseanne-as-they-drug-a-generation-is-new-low/

Drudge Highlights Ambien Side Effects After Company Mocks Roseanne - Drudge: ‘New Low’ for Ambien Maker to Mock Roseanne ‘While They Drug a Generation

Related:

The Truth About Roseanne Being Canceled - The #Roseanne Media Martyrdom Explained: The SJW, Virtue Signaler, DS Shill & Suicidal ABC Network - Ann Coulter Responds to ABC's 'Roseanne' Cancellation:

http://trumpisright.blogspot.com/2018/05/the-roseanne-media-martyrdom-explained.html

‘The Right To Try' Another Trump Promise Kept - President Donald Trump Signs 'Right To Try' Act That Helps Terminally Ill Patients - Watch Trump Sign ‘The Right To Try’ Act And Save Millions

‘The Right To Try' Another Trump Promise Kept - President Donald Trump Signs 'Right To Try' Act That Helps Terminally Ill Patients - Watch Trump Sign ‘The Right To Try’ Act And Save Millions

Related:

The Right To Try Bill is the Right Idea - Democrats Claim 'Right To Try' Act Is Racist, Guinea Pig Testing:

http://trumpisright.blogspot.com/2018/05/the-right-to-try-bill-is-right-idea.html

62.5 BILLION: Bayer To Takeover Monsanto With EU's Blessings

62.5 BILLION: Bayer To Takeover Monsanto With EU's Blessings

TOTAL CONFIRMATION: 5G Linked To Cancer By More Scientific Studies

TOTAL CONFIRMATION: 5G Linked To Cancer By More Scientific Studies

WHO: DRC Ebola Outbreak on a 'Knife's Edge' as Urban Cases Rise

An outbreak of the deadly Ebola virus in Democratic Republic of Congo has the clear "potential to expand" as the number of confirmed cases continues to rise, the World Health Organization warned.

 

Health workers' response is on an "epidemiological knife's edge" after the number of people stricken with Ebola in the DRC rose to 28 since an outbreak was detected earlier this month, said WHO Deputy Director Peter Salama, in comments made on Wednesday at a conference in Geneva, Switzerland.

 

Seven of the confirmed cases were in urban settings.

 

"The next few weeks will really tell if this outbreak is going to expand to urban areas or if we're going to be able to keep it under control," Salama said.

Following the meeting, Salama told AFP news agency the outbreak "could go either way" in coming weeks.

"We are working around the clock to make sure it [goes] in the right direction," he said.

The average fatality rate among those infected with Ebola, which has no proven cure, is about 50 percent, according to WHO. 

DRC's most recent Ebola outbreak - its ninth since the disease was first identified in 1976 - initially appeared to be confined in a rural setting near the town of Bikoro, in the central African nation's northwestern Equateur Province.

But a confirmed instance of the virus last week in the city of Mbandaka, home to 1.2 million people and about 150km away from Bikoro, plunged the ongoing crisis into a "new phase", the DRC's Health Minister Oly Ilunga said last week. 

Twenty-seven people have died and at least 58 others in DRC's northwest have shown Ebola symptoms since it was identified on May 8, according to the health ministry.
https://www.aljazeera.com/news/2018/05/drc-ebola-outbreak-knife-edge-urban-cases-rise-180523134122470.html

The big problem is that the virus has a 21 day incubation period. This makes it difficult to determine the spread of the disease based on the symptomatic patients. This is why quarantine efforts are so important.

Related:

3 Ebola-infected detainees escape forced quarantine, take a stroll through big city, 2 die, 1 recaptured

[Posted at the SpookyWeather blog, May 25th, 2018.]

LANDMARK LAWSUIT CLAIMS MONSANTO HID CANCER DANGER OF WEEDKILLER FOR DECADES

At the age of 46, DeWayne Johnson is not ready to die. But with cancer spread through most of his body, doctors say he probably has just months to live. Now Johnson, a husband and father of three in California, hopes to survive long enough to make Monsanto take the blame for his fate.

On 18 June, Johnson will become the first person to take the global seed and chemical company to trial on allegations that it has spent decades hiding the cancer-causing dangers of its popular Roundup herbicide products – and his case has just received a major boost.  

Last week Judge Curtis Karnow issued an order clearing the way for jurors to consider not just scientific evidence related to what caused Johnson’s cancer, but allegations that Monsanto suppressed evidence of the risks of its weed killing products. Karnow ruled that the trial will proceed and a jury would be allowed to consider possible punitive damages.

“The internal correspondence noted by Johnson could support a jury finding that Monsanto has long been aware of the risk that its glyphosate-based herbicides are carcinogenic … but has continuously sought to influence the scientific literature to prevent its internal concerns from reaching the public sphere and to bolster its defenses in products liability actions,” Karnow wrote. “Thus there are triable issues of material fact.”
https://www.blacklistednews.com/article/66015/landmark-lawsuit-claims-monsanto-hid-cancer-danger-of-weedkiller-for.html

[Posted at the SpookyWeather blog, May 25th, 2018.]

What Is Causing America’s Mental Illness Problem?

What Is Causing America’s Mental Illness Problem?

1980s Dietary Guidelines Made America Fat

1980s Dietary Guidelines Made America Fat

Gardasil HPV Vaccine Has Tripled Cervical Cancer In North America

Gardasil HPV Vaccine Has Tripled Cervical Cancer In North America

Neonatal Hepatitis B Vaccine, The Autism Influencer From Day One Of Life?

Is the U.S.-mandated Hepatitis B vaccine administered to newborn infants within 24 hours of birth the initial ‘impact’ vaccine for ‘programming’ a child’s unfortunate decline into the Autism Spectrum Disorder (ASD)?

The answer to that question is a resounding “YES” according to a 2016 peer review study titled, Neonatal hepatitis B vaccination impaired the behavior and neurogenesis of mice transiently in early adulthood published in the Elsevier peer review journalPsychoneuroendochrinology.

The extensive research on mice brains published above indicates what the CDC/FDA should have found and warned against as part of the licensing procedures for the Hepatitis B vaccine introduced as a recommended infant/childhood vaccine way back in 1991, when “the first dose was recommended to be administered at birth before hospital discharge or at age 1–2 months.” [3]

That apparent default by the ever-increasing-malfeasance being exposed on the part of the CDC/FDA’s either ineptness or reliance upon what’s known as “consensus science,” is proof of the absolute need for the dismantling of a federal U.S. health agency—listed on the U.S. Stock Exchange (NASDAQ) [4]—by Congress, who has oversight.

Congress should be investigating the role a ‘premiere’ U.S. federal health agency has in the ‘promoting’ of false science, or their lack of due diligence to protect U.S. citizens, all while dispensing fraudulent and/or pseudoscience to the World Health Organization and other nation states’ health agencies, which rely upon false and misleading vaccine ‘science’.

According to the J.B. Handley Blog of May 10, 2018, “Vax-Unvax study of mice implicates Hepatitis B vaccine, media silent,” (the first study that ever looked at the impact ANY vaccine might have on the brains of mice):

This work reveals for the first time that early HBV vaccination induces impairments in behavior and hippocampal neurogenesis. This work provides innovative data supporting the long suspected potential association of HBV with certain neuropsychiatric disorders such as autism and multiple sclerosis. [1-2] [CJF emphasis]

The statistically outrageous fact about the Hep B neonatal vaccine is that it is administered to approximately 70% of neonates WORLDWIDE!

According to Dr. Yao, the Hep B vaccine effects administered to mice indicated:

1. The HBV vaccine negatively impacted the behavior of mice.
2. The HBV vaccine mice experienced a spike in the cytokine IL-6.
3. It took time for the neurological impact of HBV vaccine to manifest. [Therefore, the argument of no “correlation and causation” needs to be rejected totally.]
4. They concluded with a statement that, in a sane world, would prompt the immediate cessation of Hepatitis B vaccine administration to babies. [1]

Annual immunization costs have gone from $100 per child in 1986 to $2,192 per child in 2015, the Times noted, citing data from the Centers for Disease Control and Prevention. The Times described vaccination costs today as ‘soaring’. [5] [That was in June 2015; what’s it in 2018?]

Question: Do the CDC/FDA function as ‘sane’ health agencies since they are financially supported by the pharmaceutical industry [6]; controlled by vested interests [7]; and even own patents on 54 vaccines [8]?—a definite conflict of interest!
https://www.naturalblaze.com/2018/05/neonatal-hepatitis-b-vaccine-the-autism-influencer-from-day-one-of-life.html

The bottom line with the rise in Autism is that it is caused by contaminants found in our environment. There may be many separate sources of contamination. The Hep B Vaccine may be one of them (a significant contributor). We are looking at damage to the neurological development of our children and the cover-up of what is happening to protect the profits of giant pharmaceutical companies.

[Posted at the SpookyWeather blog, May 17th, 2018.]

Ebola Returns to the Congo: 19 Dead

Ebola Returns to the Congo: 19 Dead

Grassroots Organization Is Teaching American’s How To Garden

One of the first steps in breaking free of the modern consumerist system is to learn to grow your own food.



Grassroots Organization Is Teaching American’s How To Garden

BREAKING: Cell Phones Turn Cars Into Microwaves Ovens

BREAKING: Cell Phones Turn Cars Into Microwaves Ovens

Trump unveils sweeping plan to lower prescription drug costs

Trump unveils sweeping plan to lower prescription drug costs

Related:

Trump is right: YOUR medical care IS at risk:

http://trumpisright.blogspot.com/2016/01/trump-is-right-your-medical-care-is-at.html

Orlistat Marketed as Alli is a Big, Fat Lie - Diet Drugs Work: Why Won’t Doctors Prescribe Them?

...The greatest alarm about Orlistat is its carcinogenic potential. Beginning with the list of inactive ingredients there are two known toxins—FD&C blue and the solvent Sodium Laruel Sulfate (SLS). FD&C blue is a coal tar dye, which contains heavy metals and is a possible endocrine disruptor. The greatest risk of Orlistat is that studies of the prescription version Xenical revealed that it clearly causes pre-cancerous lesions of the colon (aberrant crypt foci or ACF). On April 10, 2006 Public Citizen (the public advocacy organization that helped inform the public about the risks of Vioxx and Ephedra) petitioned the FDA, urging them to remove Xenical from the market. Despite the known hazards, the FDA not only kept Xenical on the market, it approved the OTC version Orlistat. It is shocking that despite the clinical evidence of the carcinogenic properties of the drug that the FDA has not taken a stand to protect consumers. Buyer beware.

More:

https://www.naturalnews.com/022164_orlistat_weight_health.html

Diet Drugs Work: Why Won’t Doctors Prescribe Them?
By Suzanne Koven
https://www.newyorker.com

The woman sat on my exam table and pointed to her snug paper gown. “Doctor,” she said, “I need your help losing weight.”

I spent the next several minutes speaking with her about diet and exercise, the health risks of obesity, and the benefits of weight loss—a talk I’ve been having with my patients for more than twenty years. But, like the majority of Americans, most of my patients remain overweight.

Afterward, I realized that what my patient wanted was a pill that would make her lose weight. I could have prescribed her one of four drugs currently approved by the F.D.A.: two, phentermine and orlistat, that have been around for more than a decade, and two others, Belviq (lorcaserin) and Qsymia (a combination of phentermine and topiramate), that have recently come onto the market and are the first ever approved for long-term use. (Ian Parker wrote about the F.D.A.’s approval process for new medications in this week’s issue.) The drugs work by suppressing appetite, by increasing metabolism, and by other mechanisms that are not yet fully understood. These new drugs, along with beloranib—which produces more dramatic weight loss than anything currently available but is still undergoing clinical trials—were discussed with great excitement last month by experts and researchers at the international Obesity Week conference in Atlanta.

But I’ve never prescribed diet drugs, and few doctors in my primary-care practice have, either. Donna Ryan, an obesity specialist at the Pennington Biomedical Research Center at Louisiana State University, has found that only a small percentage of the doctors she has surveyed regularly prescribe any of the drugs currently approved by the F.D.A. Sales figures indicate that physicians haven’t embraced the new medications, Qsymia and Belviq, either.

The inauspicious history of diet drugs no doubt contributes to doctors’ reluctance to prescribe them. In the nineteen-forties, when doctors began prescribing amphetamines for weight loss, rates of addiction soared. Then, in the nineties, fen-phen, a popular combination of fenfluramine and phentermine, was pulled from the market when patients developed serious heart defects. Current medications are much safer, but they produce only modest weight loss, in the range of about five to ten per cent, and they do have side effects.

Still, as Ryan pointed out, doctors aren’t always shy about prescribing medications that cause side effects and yield undramatic results. A five to ten per cent weight loss might not thrill patients, or even nudge them out of being overweight or obese, but it can improve diabetes control, blood pressure, cholesterol, sleep apnea, and other complications of obesity. And, although the drugs aren’t covered by Medicare or most states’ Medicaid programs, private insurance coverage of weight-loss drugs has improved and is likely to expand further under the Affordable Care Act, which requires insurers to pay for obesity treatment. So what prevents physicians from prescribing these drugs?

Several leading experts and researchers attending Obesity Week told me that the problem is that, while specialists who study obesity view it as a chronic but treatable disease, primary-care physicians are not fully convinced that they should be treating obesity at all. Even though physicians since Hippocrates have known that excess body fat can cause diseases, the American Medical Association announced that it would recognize obesity itself as a disease only a few months ago. These divergent views on obesity represent one of the widest gulfs of understanding between generalists and specialists in all of medicine.

Lee M. Kaplan, co-director of the Weight Center at Massachusetts General Hospital, thinks that some bias comes from the average physician’s lack of appreciation for the complex physiology of weight homeostasis. Humans have evolved to avoid starvation rather than obesity, and we defend our body mass through an elaborate system involving the brain, the gut, fat cells, and a network of hormones and neurotransmitters, only a fraction of which have been identified. Obesity, Kaplan said, which represents dysfunction of this system, is likely not one disease but dozens.

That one person’s obesity is not like another’s may explain why some people lose a lot of weight with surgery, or a particular diet or drug, and some don’t. Kaplan thinks that if more doctors understood this, they’d view obesity treatment more receptively and realistically. He said, “If I were to say to you, ‘I have this drug that treats cancer,’ and you asked me, ‘What kind of cancer?,’ and I said, ‘All cancers,’ you’d laugh, because you recognize intuitively that cancer is a heterogeneous group of disorders. We’re going to look back on obesity one day and say the same thing.”

Obesity is potentially, in part, a neurological disease. Jeffrey Flier, an endocrinologist and dean of Harvard Medical School, has shown, like others, that repeatedly eating more calories than you burn can damage the hypothalamus, an area of the brain involved in eating and satiety. In other words, Big Gulps, Cinnabons, and Whoppers have altered our brains such that many people—particularly those with a genetic predisposition to obesity—find fattening foods all but impossible to resist once they’ve eaten enough of them. Louis J. Aronne, director of the Comprehensive Weight Control Program at New York-Presbyterian/Weill Cornell Medical Center, explained to me, “With so much calorie-dense food available, the hypothalamic neurons get overloaded and the brain can’t tell how much body fat is already stored. The response is to try to store more fat. So there’s very strong scientific evidence that obesity is not about people lacking willpower.”

But this message has not found its way into society, where obese people are still often considered self-indulgent and lazy, and face widespread discrimination. Several obesity experts told me they’ve encountered doctors who confide that they just didn’t like fat people and don’t enjoy taking care of them. Even doctors who treat obese patients feel stigmatized: “diet doctor” is not a flattering term. Donna Ryan, who switched from oncology to obesity medicine many years ago, recalls her colleagues’ surprise. “I had respect,” she says. “I was treating leukemia!”

George Bray, also of the Pennington Biomedical Research Center, thinks that socioeconomic factors play into physicians’ lack of enthusiasm for treating obesity. Bray points to the work of Adam Drewnowski at the University of Washington, who has shown that obesity is, disproportionately, a disease of poverty. Because of this association, many erroneously see obesity as more of a social condition than a medical one, a condition that simply requires people to try harder. Bray said, “If you believe that obesity would be cured if people just pushed themselves away from the table, then why do you want to prescribe drugs for this non-disease, this ‘moral issue’? I think that belief permeates a lot of the medical field.”

Obesity experts with whom I spoke tended to be more optimistic than other physicians about the possibility that obesity can be treated successfully and that the obesity epidemic will be curbed. They point to exciting new research—for example, the finding that an alteration in gut bacteria, rather than mechanical shrinking of the stomach or intestine, may be what causes weight loss after gastric bypass. This raises the possibility that the benefits of surgery might become available without the surgery itself. They also note that public-health efforts seem to be reducing childhood obesity, even in poor communities. But they remain concerned that despite such promising developments, many physicians still don’t see obesity the way they do: as a serious, often preventable disease that requires intensive and lifelong treatment with a combination of diet, exercise, behavioral modification, surgery, and, potentially, drugs.

Louis Aronne thinks this will change as more physicians enter the field of obesity medicine, the physiology of obesity is better understood, and more effective treatment options become available. He likens the current attitude toward obesity to the prevailing attitude toward mental illness years ago. Aronne remembers, during his medical training, seeing psychotic patients warehoused and sedated, treated as less than human. He predicts that, one day, “some doctors are going to look back at severely obese patients and say, ‘What the hell was I thinking when I didn’t do anything to help them? How wrong could I have been?’ ”

Patients like the woman who asked me to help her lose weight may not have to wait that long. Specialists are now developing programs to aid primary-care physicians in treating obesity more aggressively and effectively. But we’ll have to want to treat it: as Kaplan argues, “Whether you call it a disease or not is not so germane. The root problem is that whatever you call it, nobody’s taking it seriously enough.”

Suzanne Koven is a primary-care doctor at Massachusetts General Hospital in Boston and writes the column “In Practice” at the Boston Globe.

Photograph by Patrick Allard/REA/Redux.